Effects of lx4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects

Clinical Therapeutics

Volumn 35, Issue 8, 2013, Pages 1162-1173.e8

  Zambrowicz, Brian ^a   Ogbaa, Ike ^a   Frazier, Kenny ^a   Banks, Phillip ^a   Turnage, Anne ^a   Freiman, Joel ^a   Boehm, Kristi A ^a   Ruff, Dennis ^b   Powell, David ^a   Sands, Arthur ^a  

^a LEXICON PHARMACEUTICALS INC   (United States)

^b Icon Development Solutions   (United States)

Author keywords

Diabetes; GLP 1; PYY; SGLT1; SGLT2; Urinary glucose excretion

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LX 4211; LX4211; PEPTIDE YY; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

ADULT; ANXIETY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DEFECATION HABIT; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEEDING BEHAVIOR; GASTROINTESTINAL DISEASE; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MEAL; MICTURITION; MULTIPLE DRUG DOSE; PHASE 1 CLINICAL TRIAL; PHLEBITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; URINALYSIS; VASCULAR DISEASE;

DIABETES; GLP-1; PYY; SGLT1; SGLT2; URINARY GLUCOSE EXCRETION;

ADULT; BLOOD GLUCOSE; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; GLUCAGON-LIKE PEPTIDE 1; GLYCOSIDES; HEALTHY VOLUNTEERS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MEALS; MIDDLE AGED; POSTPRANDIAL PERIOD; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84882831390     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.06.011     Document Type: Article

References (25)

1. Wright E.M., Loo D.D., Hirayama B.A. Biology of human sodium glucose transporters. Physiol Rev 2011, 91:733-794.
2. Powell D.R., DaCosta C.M., Gay J., et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab 2012, 304:E117-E130.
3. Powell D.R., Smith M., Greer J., et al. LX4211 increases serum glucagon-like peptide 1 and peptide levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther 2013, 345:250-259.
4. Zambrowicz B., Ding Z.M., Ogbaa I., et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther 2013, 35:273-285.
5. Zambrowicz B., Freiman J., Brown P.M., et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012, 92:158-169.
6. Dobbins R, Zambrowicz B, Liu Y, et al. Glucose transport via SGLT1 is critical for post-prandial GIP secretion in rats and humans. Presented at: American Diabetes Association Annual Meeting; June 8-12, 2012. Philadelphia, Pa.
7. Shibazaki T., Tomae M., Ishikawa-Takemura Y., et al. KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2012, 342:288-296.
8. Wright E.M.I. Glucose galactose malabsorption. Am J Physiol 1998, 275:G879-G882.
9. Rosenstock J, Zambrowicz B, Lapuerta P, et al. Impact of LX4211, a dual inhibitor of sodium glucose transporter 1 and 2, on cardiovascular risk factors in type 2 diabetes. Presented at: American Heart Association Annual Meeting; Nov. 3-7, 2012. Los Angeles, Calif.
10. Port A, Macha S, Seman L, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 10773, a sodium-glucose co-transporter inhibitor (SGLT-2), in healthy volunteers. Presented at: American Diabetes Association Annual Meeting; June 25-29, 2010. Orlando, Fla.
11. Polidori D., Sha S., Mudaliar S., et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 2013 Feb 14, [Epub ahead of print].
12. Sha S., Divineni D., Ghosh A., et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011, 13:669-672.
13. Newcombe R.G. Latin square designs for crossover studies balanced for carryover effects. Stat Med 1992, 11:560.
14. Cummings D.E. Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int J Obes (Lond) 2009, 33(Suppl 1):S33-S40.
15. Meirelles K., Ahmed T., Culnan D.M., et al. Mechanisms of glucose homeostasis after Roux-en-Y gastric bypass surgery in the obese, insulin-resistant Zucker rat. Ann Surg 2009, 249:277-285.
16. Nilsson A.C., Ostman E.M., Holst J.J., Björk I.M. Including indigestible carbohydrates in the evening meal of healthy subjects improves glucose tolerance, lowers inflammatory markers, and increases satiety after a subsequent standardized breakfast. J Nutr 2008, 138:732-739.
17. Zhou J., Martin R.J., Tulley R.T., et al. Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. Am J Physiol Endocrinol Metab 2008, 295:E1160-E1166.
18. Moriya R., Shirakura T., Ito J., et al. Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am J Physiol Endocrinol Metab 2009, 297:E1358-E1365.
19. Gorboulev V., Schürmann A., Vallon V., et al. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 2012, 61:187-196.
20. Ikumi Y., Kida T., Sakuma S., et al. Polymer-phloridzin conjugates as an anti-diabetic drug that inhibits glucose absorption through the Na+/glucose cotransporter (SGLT1) in the small intestine. J Control Release 2008, 125:42-49.
21. Sakuma S., Teraoka Y., Sagawa T., et al. Carboxyl group-terminated polyamidoamine dendrimers bearing glucosides inhibit intestinal hexose transporter-mediated D-glucose uptake. Eur J Pharm Biopharm 2010, 75:366-374.
22. Komoroski B., Vacchharajani N., Boulton D., et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009, 85:520-526.
23. Sarashina A, Koiwai K, Seman LJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet. 2013;28:213-219.
24. Washburn W.N., Poucher S.M. Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 2013, 22:463-486.
25. Xin B, Wang H. Multiple sequence variations in SLC5A1 gene are associated with glucose-galactose malabsorption in a large cohort of Old Order Amish. Clin Genet. 79:86-91.